Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 15th European Neurology Congress London, UK.

Submit your Abstract
or e-mail to

events@conferenceseries.com
neurologycongress@neuroconferences.org
neurologycongress@neuroconferences.com

Scientific Program Day 1
Scientific Program Day 2
Scientific Program Day 3

Day 1 :

Keynote Forum

Allal Boutajangout

New York University Langone Medical Center, USA

Keynote: Passive immunization with novel monoclonal anti-PrP antibody TW1 in an Alzheimer’s mouse model

Time : 09.30-10:20

Conference Series Neurology Congress 2017 International Conference Keynote Speaker Allal Boutajangout photo
Biography:

Allal Boutajangout obtained a PhD in Neuropathology from Free University of Brussels (ULB-Erasme Hospital), School of Medicine. He has completed his Postdoctoral training at New York University School of Medicine. He is a Research Associate Professor of Neurology and Neuroscience and Physiology. He is also the Chief of the Laboratory of Neurodegeneration and Drug Discovery Program within Center for Cognitive Neurology at NYU. He has received prestigious award Margaret M Cahn for his outstanding research in the field of Alzheimer’s and other awards from: Alzheimer association, NIH pilot grant, Toyama Company, Revalesio Company and co-investigator in several RO1 NIH grants. He has published more than 30 papers in reputed journals and serves as a reviewer for many scientific journals.

Abstract:

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with two hallmarks: Plaques seniles (PS) and Neurofibrillary tangles (NFTs). Recently, there has been much more focus on tau related pathology with the published failure of several amyloid β targeted therapeutic approaches in phase III clinical trials. Previously, we published the first active and passive immunization targeting tau pathology that was reproduced later by Citron’s group at Eli Lilly as well as by other academic groups. It has been also reported that oligomeric species of tau are thought to be critical for the “prion-like” spread of pathology and for neuronal toxicity. We have first generated a novel monoclonal anti-PrP antibody (TW1) and developed a new transgenic model for AD that express mutated PS1 and all human tau isoforms on a murine tau knockout background (hTau/PS1 Tg mice). This model has an earlier onset (at < 3 months of age) and more rapid progression of tau pathology than prior htau mouse model. In this study, passive immunization with our new monoclonal antibody TW1 didn’t show any difference in sensorimotor tests including traverse beam, rotarod and locomotor activity but improves cognitive decline in two cognitive tasks: short term memory (recognition object) mice treated spent more time with the novel object compared to the old object and differed significantly between both groups treatment effect between treated and non-treated animals showed a significant difference, One tailed t-test students p=0.025, and with closed field symmetrical maze (Day 1 two tailed, t-test P=0.0001; Day2 two tailed, t-test P=0.0015; Day3 two tailed, t-test P=0.0002). Reduction of tau pathology was observed in the motor cortex, hippocampus and piriform cortex of the animal treated with TW1 compared to controls. No significant difference was observed between both groups with GFAP antibody. Further analysis is underway. Passive immunization with a novel monoclonal anti-PrP decreases tau pathology by immunotherapy and improves cognitive decline in AD mouse model. 
 

Keynote Forum

Yuri P Danilov

University of Wisconsin-Madison, USA

Keynote: Translingual Neurostimulation (TLNS): A novel approach to neurorehabilitation
Conference Series Neurology Congress 2017 International Conference Keynote Speaker Yuri P Danilov photo
Biography:

Yuri Danilov is a system neuroscientist with over 35 years’ experience in research on brain functions and the special senses. He is the lead discoverer of the balance retention effect, lead development of the specific training regimens, and continues to identify potential clinical and non-clinical application of neuromodulation and sensory substitution technology. He received the M.S. degree in biophysics and the Ph.D. degree in neuroscience, in 1984, from the Pavlov Institute of Physiology, USSR Academy of Science. He is a co-inventor the CN-NINM technology and his interest areas are neuroplasticity, neurorehabilitation, enhancement of human performance.

Abstract:

Cranial nerve non-invasive neuromodulation (CN-NINM) is new technology, that represents a synthesis of a new non-invasive brain stimulation technique with applications in physical medicine, cognitive, and affective neurosciences. CN-NINM is a method of intervention that combines Translingual Neurostimulation (TLNS), using the Portable neurostimulation Stimulator (PoNS™) device, and targeted training designed for movement control rehabilitation. Our new stimulation method appears promising for the treatment of a full spectrum of movement disorders, and for both attention and memory dysfunction associated with traumatic brain injury. The integrated CN-NINM therapy proposed here aims to restore function beyond traditionally expected limits by employing both newly developed therapeutic mechanisms for progressive physical and cognitive training - while simultaneously applying brain stimulation through a portable neurostimulation device PoNS™. Based on our previous research and recent pilot data, we believe a rigorous in-clinic CN-NINM training program, followed by regular at-home exercises that will also be performed with CN-NINM, will simultaneously enhance, accelerate, and extend recovery from multiple impairments (e.g. movement, vision, speech, memory, attention, and mood), based on divergent, but deeply interconnected neurophysiological mechanisms of neuroplasticity.

Keynote Forum

Khin Bo

Northern Lincolnshire & Goole NHS Foundation Trust, UK

Keynote: Multiple Sclerosis, Corpus Callosum & Bediside Test
Conference Series Neurology Congress 2017 International Conference Keynote Speaker Khin Bo photo
Biography:

Khin Bo is involved in NeuroRehabilitation over 20 years. He is also a Lecturer (Hon) in Hull and York Medical School teaching 4th Year Medical Students in CNS and Musculoskeletal Blocks. He is doing Botulinum Toxin injection in Spasticity, Dystonia and Involuntary Movement disorders over 15 years and done Poster presentations and Oral Presentations in International Neuro Rehabilitation Conferences. He is also involved in using Functional Electrical Stimulation (FES) over 10 years and presented regularly in International FES Conferences. He is working on developing Hypertonic Hand Monitoring Scale.
 

Abstract:

Demyelination affects highly myelinated structures like Corpus Callosum (CC). CC is unique in function that it connects right and left hemisphere. It synchronises bimanual or bipedal activities. Affecting CC can disturb synchrony between the two hemispheres will affect bimanual and bipedal tasks. The aim is to see if speed of clapping (bimanual activity) can reflect the involvement of CC in Multiple Sclerosis. Consecutive 70 Multiple Sclerosis patients from Outpatient clinics and Home visits were tests for bimanual hand function (clapping) .Exclusion criteria are upper limb power <3/5 MRC scale, Pain, Visual impairment, Intentional tremors, Stroke or Cognitive impairment. Study period started from 01 09 2016. Comparison of speed between rapid supination/pronation of left and right hand separately and then clapping of both hands( supination/pronation of each hands alternatively). Patients had to do as fast as they could. Noticeable slowing of clapping comparing to single hand supination/pronation was taken as a sign slowing down of conduction through CC. 31 patients were excluded, 34 patients showed no noticeable difference, 2 patients were difficult to make conclusions and 3 patients showed definite slowing down in clapping. Positive patients will have difficulties in doing bimanual activities like using two sticks for mobility, typing using keyboard, pushing wheel chair bimanually etc. etc.. It is possible to detect CC involvement by doing above bedside test and can be used in Rehabilitation Setting. Sample size is not large enough and larger studies need to follow to validate the finding.

Keynote Forum

Evelyn M Garcia

Virginia Tech Carilion School of Medicine, USA

Keynote: System based practice requires a holistic approach: From the heart to the brain
Conference Series Neurology Congress 2017 International Conference Keynote Speaker Evelyn M Garcia photo
Biography:

Evelyn M. Garcia is the Chairman and Medical Director of Carilion Clinic Radiology and Chairman and Assistant Professor of Radiology of Virginia Tech Carilion School of Medicine.  She is a member of the American College of Radiology Appropriateness Criteria Abdomen 2 Panel with fellowship training in Body Magnetic Resonance Imaging and additional Board Certification in Cardiovascular Computed Tomographic Angiography.  She serves as a member of the board of the Virginia Chapter of the American College of Radiology, is an elected member of the Alpha Omega Alpha Medical Honor Society, serves on multiple boards and committees for Carilion Clinic and serves as the Radiologist for the multi-disciplinary structural heart valve team.

Abstract:

Across the globe people are enjoying greater longevity.  With greater lifespan comes increasing rates of structural heart disease and its dire complication, cardioembolic stroke.  Aortic stenosis is the most prevalent cardiac valvular disease in the Western world. Because of advanced age and comorbidities, 30% of aortic stenosis patients are not surgical candidates.  Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) is rapidly becoming the standard treatment in this patient population and being expanded to encompase populations of younger patients as an alternative to surgical aortic valve replacement (SAVR).  Stroke is one of the most feared complications of TAVI/TAVR with an incidence ranging from 3.4-8% of patients. 
 
Stroke is the 4th leading cause of death in the Unites States and 2nd leading cause of death in the EU and Europe.  Twenty percent of stroke patients have cardiogenic sources of emboli with 50% of those related to non-valvular atrial fibrillation and greater than 90% of thrombi originating in the left atrial appendage (LAA).  In one study, greater than 55% of patients with first time stroke and known non-valvular atrial fibrillation were on anticoagulation therapy, 68% were found to be subclinical.  Percutaneous procedures have been developed to address the risk of cardioembolic stroke for those patients in whom standard medical therapy is contraindicated.  LAA occlusion is available to this patient cohort with multiple device options and variable routes of deployment.  Embolic events have been documented during LAA occlusion procedures with variable sources of embolic material identified through pathologic analysis of debris.  As we treat the heart we must be cognizant of the impact on the brain.  Total ischemic lesion volume of 1.5-4.3 cm3 equates to the death of approximately 2 million neurons and the decoupling of 1 billion synapses.  The future of minimally invasive structural heart interventions must be married with the combination of endovascular protection and neuroendovascular intervention to treat the whole patient.